Bilateral Breast Cancers Followed by Metastatic Disease and Long Eribulin Treatment

Patient Info: Anonymized, female, 50s | Stage IV

Biomarkers: Left primary: ER 90%, HER2 FISH not amplified, Ki67 25%. Right primary: ER 90%

Metastatic Site: lung, pleura, liver, bone

After pelvic bone metastases appeared in 2017, she stopped eribulin, received pelvic radiation and remained on fulvestrant treatment.

PubMed CentralRead more →

Metastatic Breast Cancer With Durable Liver and Peritoneal Response to Eribulin

Patient Info: Anonymized, female, 50s | Stage IV

Biomarkers: Initial tumor: ER 90%, PgR 70%. Liver metastasis: ER 60%, HER2 1+

Metastatic Site: liver, peritoneum

While continuing eribulin beyond 34 cycles, her liver disease was stable and the peritoneal response persisted after earlier major tumor reduction.

PubMed CentralRead more →

Metastatic Breast Cancer With Brain, Bone, Lung and Liver Disease Responding During Eribulin Treatment

Patient Info: Anonymized, female, 40s | Stage IV

Biomarkers: Initial tumor: ER 90%, HER2 negative, Ki67 10%. Lung metastasis: ER 90%

Metastatic Site: lung, bone, brain, liver

Eribulin remained ongoing with reduced brain lesions, stable bone disease and continued shrinkage of liver metastases after prior systemic progression.

PubMed CentralRead more →

Breast cancer returning 21 years later as a solitary parotid metastasis

Patient Info: Anonymized, Female, 70+ | Stage IV

Biomarkers: Parotid metastasis ER positive; PR positive; HER2 borderline by IHC but FISH 1.82

Metastatic Site: left parotid gland

More than 5 months after the parotid metastasis was diagnosed, the tumour had slightly decreased in size and her metastatic disease remained stable on endocrine therapy.

PubMed CentralRead more →

Breast cancer returning years later in the biceps muscle

Patient Info: Anonymized, Female, 60s | Stage IV

Biomarkers: ER positive

Metastatic Site: left biceps muscle

Her arm symptoms improved considerably after radiotherapy, and MRI 6 months later showed a significant decrease in the size of the biceps tumour.

PubMed CentralRead more →

Stage II Breast Cancer: Natalia's Survivor Story

Patient Info: Natalia | Stage II

Natalia was declared cancer-free on February 21, 2024, and continued regular follow-up while taking letrozole.

Our Cancer StoriesRead more →

Stage II Breast Cancer: Tasha's Patient Story

Patient Info: Tasha | Stage II

She completed surgery and radiation and is doing well as a survivor while continuing tamoxifen.

Our Cancer StoriesRead more →

Mixed epithelial and mesenchymal metaplastic breast carcinoma: no recurrence 1 year after surgery and adjuvant therapy

Patient Info: Anonymized, Female, 40s

Biomarkers: Mixed metaplastic breast cancer: epithelial part ER/PR/HER2-positive; mesenchymal part ER/PR-negative with weak HER2. Ki-67 ~20%.

As of March 2014, she was doing well with no recurrence or metastasis 1 year after modified radical mastectomy, adjuvant CEF/Taxotere chemotherapy, and tamoxifen.

PubMed CentralRead more →

Breast invasive ductal carcinoma with coexisting inflammatory myofibroblastic tumor: disease-free after mastectomy, TAC, and tamoxifen

Patient Info: Anonymized, Female, Under 40

Biomarkers: Breast cancer: ER/PR-positive with HER2 2+ and p53-positive. Separate inflammatory myofibroblastic tumor had ALK/vimentin/actin/S-100 markers.

As of August 2013, she remained disease-free 2 years after modified radical mastectomy, 6 courses of TAC chemotherapy, and tamoxifen.

PubMed CentralRead more →

Localized hormone receptor-positive breast cancer disease-free 5 years after endocrine therapy switch

Patient Info: Anonymized, Female, 40s

Biomarkers: ER-positive; PR-positive; HER2-negative; low Ki-67; Oncotype DX 12

After lumpectomy and 36 months of adjuvant hormonal treatment, she remained disease-free at her last examination in March 2013, 5 years after diagnosis.

PubMed CentralRead more →

ER/PR-positive mucinous breast cancer treated with mastectomy and tamoxifen

Patient Info: Anonymized, Female, Under 40

Biomarkers: ER-positive; PR-positive; HER2/neu not overexpressed; no pathogenic BRCA1 or BRCA2 mutations identified; chromosome 13q34 duplication

After radical right mastectomy with nipple and areola preservation followed by tamoxifen, she showed no evidence of local recurrence or metastasis of breast cancer.

PubMed CentralRead more →

BRCA1-associated right invasive ductal carcinoma followed by left acinic cell carcinoma of the breast

Patient Info: Anonymized, Female, 40s

Biomarkers: Constitutional BRCA1 mutation. Right breast cancer was ER/PR positive, HER2 negative; later left tumor was triple-negative with TP53 change.

After treatment for right invasive ductal carcinoma and later contralateral acinic cell carcinoma, she was alive and well 19 months after the acinic cell carcinoma surgery, with no evidence of disease while continuing hormonal therapy.

PubMed CentralRead more →

Metastatic lobular breast cancer to bladder trigone: partial response to tamoxifen

Patient Info: Anonymized, Female, 60s | Stage IV

Biomarkers: progesterone receptor-positive; genetic testing including BRCA1 negative

Metastatic Site: bladder trigone

As of January 2012, urge incontinence had resolved and PET showed decreased activity in the breast and bladder trigone lesions nearly 10 months after starting tamoxifen, consistent with clinical and partial radiologic remission.

PubMed CentralRead more →

Lobular breast cancer with extraocular muscle and lung metastases: ocular improvement after radiotherapy and tamoxifen

Patient Info: Anonymized, Female, 60s | Stage IV

Biomarkers: Original breast cancer: ER-negative; PR-negative. Extraocular muscle metastasis/recurrent disease: ER strongly positive; PR strongly positive.

Metastatic Site: bilateral extraocular muscles, right upper lobe lung,…

At 18 months after presentation with extraocular muscle metastases, PET showed no abnormality, diplopia had resolved, and ocular motility had markedly improved, with mild bilateral ptosis remaining.

PubMed CentralRead more →

Male invasive papillary breast cancer: mastectomy and tamoxifen with 2-year well status

Patient Info: Anonymized, Male, 70+ | Stage I

Biomarkers: ER-positive; HER2 not over-amplified

Recovered after mastectomy and sentinel node biopsy, received adjuvant tamoxifen, and remained well 2 years after surgery.

PubMed CentralRead more →

Male invasive ductal breast cancer treated with mastectomy and tamoxifen

Patient Info: Anonymized, Male, 70+

Biomarkers: ER-positive

Treated with mastectomy, negative sentinel lymph node biopsy, and adjuvant tamoxifen; remained well 4 years after surgery.

PubMed CentralRead more →

ER-positive breast cancer recurrence after DCIS: chemotherapy, nodal surgery, radiation, and endocrine therapy

Patient Info: Anonymized, Female, 40s

Biomarkers: Recurrent invasive breast cancer: ER-positive; HER2/neu-negative. PR not reported.

Disease-free for 33 months after treatment of ER-positive, HER2-negative invasive breast cancer recurring in the mastectomy skin flap with positive axillary sentinel nodes.

PubMed CentralRead more →

Male ER/PR-positive breast cancer with contralateral DCIS: mastectomy and tamoxifen with no recurrence

Patient Info: Anonymized, Male, 60s

Biomarkers: Left breast cancer was ER+/PR+ with weak HER2. Right breast had intermediate-grade DCIS; no node spread reported.

Well with no evidence of locoregional recurrence after 5 years of follow-up on adjuvant tamoxifen after bilateral breast surgery.

PubMed CentralRead more →